1. Introduction {#sec0005}
===============

Inorganic arsenic (iAs) at high doses is a known human carcinogen to urinary bladder, lung and skin [@bib0005]. In addition to carcinogenic effects, recent data suggest that chronic high exposure to iAs may also contribute to other non-carcinogenic health effects such as cardiovascular diseases, obesity, diabetes, developmental defects, and respiratory diseases [@bib0010], [@bib0015], [@bib0020].

iAs has been proposed as a threshold carcinogen for at least two decades [@bib0025], [@bib0030], [@bib0035], [@bib0040]. However, methods used have been inadequate to address this in a statistically rigorous fashion [@bib0035], although data from epidemiology studies, in animals, and *in vitro* as well as mechanistic research clearly support the likelihood that iAs toxicity has a threshold dose below which health effects are not expected [@bib0040]. Although the threshold question for iAs remains highly controversial [@bib0045], [@bib0050], recent evidence supports the possibility of a threshold for iAs-induced cancer and toxic effects, including *in vitro* studies [@bib0055], [@bib0060], [@bib0065], animal studies [@bib0070], [@bib0075], and epidemiologic investigations [@bib0080], [@bib0085], [@bib0090], [@bib0095], [@bib0100]. Strikingly consistent no-effect levels have been reported in animal models (approximately 1 ppm in water or diet) [@bib0040] and *in vitro* (\>0.1 μM trivalent arsenicals) [@bib0040], [@bib0055], [@bib0060]. A general lack of increased (*e.g*., bladder) cancer risk in human populations exposed to arsenic in drinking water at concentrations below 100--150 ppb [@bib0040], [@bib0080], [@bib0095], [@bib0100] is consistent with the associated non-cytotoxic internal concentrations of trivalent arsenic metabolites (*e.g*., \<0.1 μM) in urine. Recent evidence is also consistent with thresholds for non-cancer endpoints of iAs exposure [@bib0040], [@bib0075], [@bib0085], [@bib0090]. A practical threshold for cancer induced by exposure to iAs is thus possible in view of evidence that regenerative cell proliferation associated only with cytotoxic levels of iAs exposure consistently precedes iAs-exposure-induced epithelial tumors, such as urinary bladder, skin, and lung carcinomas [@bib0040], [@bib0060], [@bib0065]. Chemically induced regenerative cell proliferation, in turn, is a response to induced cell killing that for many chemicals is expected to have a threshold-like, S-shaped dose-response [@bib0105], as is the case for a wide array of metals (including iAs) and oxidative chemicals that stimulate the cytoprotective Nrf2-mediated antioxidant response element (ARE) pathway that generally is cytoprotective at relatively low levels of increased expression [@bib0110], [@bib0115], [@bib0120].

Low-dose nonlinearity for arsenic-induced cytotoxicity *in vitro* is suggested by data reported in previous studies done using various cell lines [@bib0065], [@bib0105], [@bib0125], [@bib0130], [@bib0135]. However, relatively small replicate numbers used in such studies limited their statistical power to resolve details of cytotoxic dose-response observed low concentrations, including those associated with relatively small departures from background response levels. The present study aimed to develop more detailed data adequate to assess whether the low-dose dose-response pattern exhibited by reductions in cell viability *in vitro* following exposure to trivalent arsenic is consistent with a linear or nonlinear (*e.g*., threshold-like) pattern. This study used more than 50 assay replicates conducted at 14 iAs concentrations specially selected to focus specifically on the initial portion of the low-dose dose-response curve for reduced cell viability. For reasons of practical feasibility in a first study conducted at this level of detail, a key limitation of the study design was that concentration effects were investigated using only a single cell line and single (MTT) assay method, with the recognition that broader generalizations concerning observed response patterns can only be based on results of similarly detailed studies using additional cell types and cytotoxicity assay methods.

2. Methods {#sec0010}
==========

2.1. Materials {#sec0015}
--------------

Sodium arsenite (NaAsO~2~) (NaAs^III^) (99% purity as certified by the vendor) purchased from Sigma (St. Louis, MO) was used without additional analysis. A 10 mM stock solution was prepared in Dulbecco's PBS 1X (Gibco, Grand Island, NY). Treatment solutions of As^III^ at concentrations (*C~i~*) of 0.25, 0.5, 1, 2, 3, 4, 5, 7, 10, 15, 20, 25, and 30 μM, were prepared in cell culture medium fresh on the day of treatment. Levels of iAs, monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA) were determined for Dulbecco's PBS 1X and cell culture medium using hydride generation-atomic absorption spectrometry coupled with cryotrap (HG-CT-AAS). For Dulbecco's PBS 1X, the concentration of iAs was 0.187 ng/mL, and concentrations of MMA and DMA were below the detection limit (0.05 ng arsenic/mL for both). In the cell culture medium, concentrations were below the detection limit for iAs (0.1 ng arsenic/mL), MMA and DMA. The 13 test concentrations were selected, based on preliminary experiments and analysis of data from a previous study of As^III^-induced cytotoxicity in HEK001 cells [@bib0065], to yield a relatively detailed expected characterization of dose-response for As^III^-induced cytotoxicity, including at relatively low levels of this response in the range of 85% to 100% viability relative to unexposed cells.

2.2. Cell culture {#sec0020}
-----------------

The HEK001 human keratinocyte cell line, derived from normal human skin and immortalized by transfection of HPV-16 E6 and E7 genes (expressing keratin 14 but not keratin 10, characteristic of basal keratinocytes) [@bib0140], was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). Cells were cultured in Keratinocyte-SFM (1X) containing 5 ng/mL human recombinant EGF without bovine pituitary extract, and supplemented with 5 mL Glutamax™ (all from Gibco) and 100 units/ml penicillin and 100 μg/mL streptomycin (Hyclone, Logan, UT) at 37 °C in 5% CO~2~. As^III^ was undetectable in the medium. Visual examination of the cultured cells under a phase contrast light microscope showed cells with rounded to columnar morphology. The karyotype for the cell line is 71‐86,XXY,+1,‐2,+3,+5,‐6,+7,+8,+9,‐10,+11,‐12,+13,+14,+16,add(17)(p11.2),+18,+19,+20,+20,+2‐9mar\[cp20\]. Cytogenetic analysis revealed the presence of an abnormal hypertriploid clone characterized by loss of chromosomes 2, 6, 10, and 12; gain of chromosomes 1, 3, 5, 7, 8, 9, 11, 13, 14, 16, 18, 19, 20, and several marker chromosomes; and additional material of unknown origin on the short arm of chromosome 17. The cp abbreviation denotes that the karyotype is a composite, due to karyotypic heterogeneity and chromosome complexity and morphology within the cells analyzed. Cells used for the study were passage 3 through passage 9.

2.3. Determination of cell viability {#sec0025}
------------------------------------

Ninety-six well plates were seeded with approximately 6000 cells/well. Each plate contained eight control wells (C = 0 μM As^III^ + growth medium), eight wells at each of the eight lowest concentrations (0.25 μM ≤ *C~i~* ≤ 7 μM), four wells at each remaining concentration (*C~i~* ≥ 10 μM), and four wells containing growth medium but no cells for use as assay blanks. Twenty-four hours after seeding, treatment with As^III^ at the concentrations listed above was begun and continued for 72 h, a treatment period selected based on previous similar studies including from our own laboratory showing that period to be adequate to reliably elicit an approximate maximal magnitude of measured cytotoxicity using the MTT assay [@bib0065], [@bib0130]. At the end of the treatment period, cell viability was determined by the MTT assay [@bib0145]. Absorbance (optical density, S) of each well was determined at 570 nm using a microplate reader (Bio-Tek Elx800, Winooski, VT). Estimated viability (S*~i~*) in the *i*^th^ concentration group of treated cells on each plate was re-expressed as a corresponding percentage viability (PS*~i~* = 100% S*~i~*/S~o~); in other words as a ratio of exposed cell viability (S*~i~*) relative to the control (unexposed) cell viability (S~o~) measured on that plate. A total of 54 plates from eight experiments conducted over a 4-month period were analyzed in this way ([Table 1](#tbl0005){ref-type="table"}). Preliminary experiments using unexposed and exposed HEK001 cells cultured as described demonstrated no significant effect of plate-specific well position on measured viability (data not shown).Table 1LNS model fits to plate-specific viability data and related statistics*.*[a](#tblfn0005){ref-type="table-fn"}, [c](#tblfn0015){ref-type="table-fn"}Table 1Plate (*j*)N~x~N~p~*i~j~*PP~o~*b* (%/μM)GM (μM)GSDR^2^p~fit,adj~111470.0270.09489.218.31.150.9580.9952114100118.17.91.530.9500.995311420.0950.0857.4619.51.240.9720.995411420.1010.0928.7619.81.280.9760.9955216100113.17.21.530.8810.995621640.0190.05193.416.61.280.9680.9957216100.095102.21.41.200.8670.9958216100.05661.718.81.330.7910.9959216100.070101.16.21.340.8910.9951031830.1060.02485.813.41.400.9830.9951131810.0340.02174.311.21.450.9700.9951231810.1420.01598.712.61.470.975\<10^−7^1341820.2770.0508.9315.11.460.937∼01441840.3590.0454.2615.91.340.9650.9951541890.41800.41917.61.530.9400.0611641830.28404.5417.51.500.9310.6651741840.2500.0283.1414.91.580.9590.9951841860.3300.0581.4417.41.270.9350.6841951920.19208.5413.61.530.9630.9952051920.2000.0237.9512.81.530.9400.4352151910.1050.035108.13.01.400.951\<10^−4^2251930.2140.0327.5316.11.290.829\<10^−4^2351920.2150.0269.0614.21.390.90910^−8^2451920.2250.0249.7314.61.450.8530.995256630.1030.041104.14.51.430.95310^−5^266630.1620.0924.8518.51.460.9070.995276610.0110106.18.01.420.9040.995286630.0850.0855.5117.71.370.9140.995296620.17908.5517.81.460.9570.995306670.2930.1199.6919.91.040.7930.115317840.2750.0133.2820.71.520.8510.995327880.3180.1140.88322.21.120.9530.995337820.2690.05616.720.11.350.9260.995347820.25808.7915.11.720.8180.995357890.20900.43422.61.440.8950.9953678100.2910.1230.41623.51.010.9490.995377840.2690101.22.11.420.8070.995387820.372017.118.81.470.8490.995397820.0670.1138.4513.71.770.9330.995407830.3170.0855.8421.51.170.7900.995417810099.817.41.690.8270.995427810.03708.9716.51.850.8470.995438920.174013.021.71.470.8800.995448920.16507.3617.61.560.9460.995458930.1350.1604.7220.61.210.9090.995468950.29101.5519.81.530.9660.995478920.1070.1267.4320.81.220.9370.995488910.2150.07318.2119.61.350.9290.995498910.2390.09216.719.61.370.9460.995508970.1780.11718.820.41.270.9660.995518970.2610.11228.721.21.130.8960.995528940.142083.720.51.540.9490.995538930.2070.1237.7620.71.170.9410.995548930.0790.04043.018.81.430.9630.995AM[a](#tblfn0005){ref-type="table-fn"}All----0.1720.048335.017.91.400.9150.829SD[a](#tblfn0005){ref-type="table-fn"}All----0.1130.046241.42.970.1730.05460.353SEM[a](#tblfn0005){ref-type="table-fn"}All----0.0150.00635.640.4040.02360.00740.048AM[a](#tblfn0005){ref-type="table-fn"}, [b](#tblfn0010){ref-type="table-fn"}--[b](#tblfn0010){ref-type="table-fn"}----0.1510.051135.116.91.410.9520.821SD[a](#tblfn0005){ref-type="table-fn"}, [b](#tblfn0010){ref-type="table-fn"}--[b](#tblfn0010){ref-type="table-fn"}----0.0910.041941.22.940.1380.01720.362SEM[a](#tblfn0005){ref-type="table-fn"}, [b](#tblfn0010){ref-type="table-fn"}--[b](#tblfn0010){ref-type="table-fn"}----0.0170.00797.760.5550.02610.00330.068[^2][^3][^4]

2.4. Data analysis {#sec0030}
------------------

The value and variance of PS*~i~* were estimated as E(PS*~i~*) ∼100%{\[E(S)/E(S~o~)\] (1 +$\gamma_{0}^{2}$)} (reflecting a 1st-order correction for ratio-estimation bias) and Var(PS*~i~*) ∼\[E(S*~i~*)/E(S~o~)\]^2^ ($\gamma_{i}^{2}$ + $\gamma_{0}^{2}$), respectively, where *γX* = SD(*X*)/E(*X*) = the coefficient of *X*-variation for *X* = S*~i~* or S~o~, and E(*X*), Var(*X*), and SD(*X*) = \[Var(*X*)\]^1/2^ denote the expected value, variance, and standard deviation of *X*, respectively [@bib0150]. Because preliminary data analyses indicated substantial, unanticipated variability in observed patterns of viability dose-response, viability data for each plate were analyzed in two stages. First, plate viability data were fit as a function of As^III^ concentration *C* to the following generalized lognormal cell-viability model (LNS)

In this model, *P*~o~ is the fraction of HEK001 cells that appeared to be relatively resistant (RR) to As^III^-induced viability reduction in each assay conducted, *P* is the assumed fraction of cells appeared to be relatively highly susceptible or hypersusceptible (HS) to As^III^-induced viability reduction, and *b* is a rate constant governing assumed 1st-order loss of HS cells exposed to As^III^. In Eq. [(1)](#eq0005){ref-type="disp-formula"}, ln denotes the natural logarithm, Φ(*z*) denotes the cumulative standard normal distribution function evaluated at argument *z*, and *z* here involves functions of the geometric mean (GM) and geometric standard deviation (GSD) governing assumed lognormal loss of the remaining fraction, 1-- *P*~o~ −*P*, of As^III^-exposed cells. This remaining fraction represents those HEK001 cells in each assay that appeared to exhibit an intermediate or typical-sensitivity (TS) response to As^III^ cytotoxicity---the level of sensitivity that was observed to pertain to most of the HEK001 cells examined in each assay. Eq. [(1)](#eq0005){ref-type="disp-formula"} implies that as *C* increases, *F*(*C*) increases from *F*(0) = *P*~o~ to a limiting value of *F*(∞) = 1--*P*.

In stage 1, the LNS model was fit to plate-specific estimates of *C~i~*-specific viability (PS*~i~*) by nonlinear weighted least-squares regression (NLWLSR), using inverse variances estimated as described above as weights [@bib0155], [@bib0160], and corresponding regression-explained fraction of total plate-specific PS*~i~* variance (R^2^) and chi-square goodness of fit statistics were also calculated.

In stage 2, data were combined over all plates and modeled as follows to characterize the dose-response relationship for As^III^ cytotoxicity specifically in TS cells defined above. Estimated PS*~i~* values for each plate *j* were adjusted as follows$$\text{P}\text{S}_{i,j}^{\text{adj}} = (PS_{i} - 100\% P_{o})/(1 - P_{o} - P),\mspace{9mu} i = i_{j},...13,\mspace{9mu} j = 1,...,54$$to reflect conditioning on LNS-model parameter values of *P*~o~ = *P* = 0---that is, to represent a purely lognormal (LN) model of viability of TS cells. The initial concentration index *i~j~* ≥ 1 used for each *j*^th^ plate was calculated as Min(*i*) over indices *i* $\in$ {1,...,13} conditional onwhere *F*~LNS~ is the LNS model (Eq. [(1)](#eq0005){ref-type="disp-formula"}) fit to PS*~i~* estimates obtained for plate *j*, and *F*~LNS~^−1^(*p*) denotes the concentration predicted by this model at viability-response level PS = 100*p*% (0 ≤ *p* ≤ 1). Condition 3 thus excludes from $\text{P}\text{S}_{i,j}^{\text{adj}}$ all those points in PS*~i~* for plate *j* at which the response predicted by the LNS model for this plate is likely to be due only to HS cells. Eq. [(2)](#eq0010){ref-type="disp-formula"} and Condition 3 thus jointly imply that models fit to each *j*^th^ set of $\text{P}\text{S}_{i,j}^{\text{adj}}$ data characterize a response that pertains only to TS cells, and not to either HS or RR cells.

Mean values of combined plate-specific $\text{P}\text{S}_{i,j}^{\text{adj}}$ data at each concentration *C~i~*, weighted by the inverse-square of its respective standard error of the mean (SEM), were then fit numerically by NLWLSR as described above to LN, Cubic (C), Linear-Cubic (LC), and Hormetic-Cubic (HC) dose-response models defined by Eqs. [(4)](#eq0020){ref-type="disp-formula"}--[(7)](#eq0035){ref-type="disp-formula"}, respectively:

These fits were obtained for the entire set of 54 plates examined, and for a subset of (28) of "best-fit" plates for each of which a relatively predictive fit was obtained (R^2^ ≥ 0.91), together with an estimate of the LNS initial-slope parameter *b* that was not relatively small (*b* ≥ 2). The latter condition served to reduce ambiguity concerning the estimated LNS parameter *P* during stage 2 of data analysis.

Assessments of PS and $\text{P}\text{S}_{i,j}^{\text{adj}}$ data normality were done by Shapiro-Wilk tests [@bib0165], corresponding variance homogeneity was assessed by Bartlett's tests [@bib0170], and p-value adjustments to corresponding p~adj~ values that account for multiple independent tests performed were done by Hommel's modified Bonferroni procedure [@bib0175]. Nested F-tests, yielding statistics F~df,df2~ with df1 and df2° of freedom, were used to assess the significance of improved fits by PS~LC~(*C*) and by PS~HN~(*C*) each compared to PS~C~(*C*) [@bib0180]. To compare means of $\text{P}\text{S}_{i,j}^{\text{adj}}$ data, parametric one-way analysis of variance or (where indicated in case of unequal variances) nonparametric Kruskal-Wallis (KW) tests were used [@bib0170], [@bib0185]. All calculations were performed using *Mathematica* 10.2^®^ [@bib0160].

3. Results {#sec0035}
==========

MTT measures obtained for 216 blank wells had an average (±1 SD) value of 0.000037 (±0.0014). The eight batches of plate-specific control measures (S~o~) were each approximately normally distributed with means of 0.592--0.842 and had unequal variances (p \< 10^−7^, by Shapiro-Wilk test); the batch-specific means differed significantly (p \< 10^−7^, by Kruskal-Wallis test). The combined 54 sets of plate-specific sets of S~o~ measures obtained had an average (±1 SD) value of 0.731 (±0.107), each of these sets was approximately normally distributed (p~adj~ \> 0.13), and all sets combined had significantly unequal variances (p = 0.000052) and means (p = ∼0, by KW test). The latter observation justified characterizing viability data on a plate-specific basis. Summaries of unadjusted viability (PS) data and corresponding LNS-model fit statistics obtained for each plate are listed in [Table 1](#tbl0005){ref-type="table"}, based on MTT cell-viability measures obtained for nearly 5000 control and treated wells (see [Table 1](#tbl0005){ref-type="table"}, note c). Of the 54 LNS-model fits summarized in [Table 1](#tbl0005){ref-type="table"}, only four are clearly inconsistent (p~fit,adj~ ≤ 0.01) with the modeled data conditional on the estimated errors in estimated mean response, but all fits nevertheless predict those mean-response patterns reasonably well (0.790 ≤ R^2^ ≤ 0.983). Six of the variables (N~p~, *P*, *P*o, *B*, R^2^, p~fit,adj~) defined in [Table 1](#tbl0005){ref-type="table"} exhibited no significant Pearson product-moment correlations (p~adj~ \> 0.20), except for a negative association between estimates for LNS model parameters *b* and *P* (*r* = −0.66, p~adj~ = 10^−7^). A similar correlation pattern and similar summary statistics for estimated parameters and LNS-model fits were obtained for a subset of 28 "best-fit" plates ([Table 1](#tbl0005){ref-type="table"}). Individual LNS-model fits to these 28 data sets appear in Supplemental Materials.

Adjusted viability data (defined by Eq. [(2)](#eq0010){ref-type="disp-formula"}) that were combined for dose-response analysis are summarized in [Table 2](#tbl0010){ref-type="table"}. Fits of LN, Cubic, LC, and HC models obtained to the complete set of adjusted data, and to the "best-fit" data subset, are shown in [Fig. 1](#fig0005){ref-type="fig"}, [Fig. 2](#fig0010){ref-type="fig"}, respectively. Corresponding fit details and statistics are listed in [Table 3](#tbl0015){ref-type="table"}. Using data from all *n* = 54 plates as well as only from the 28 "best-fit" plates, approximately equal levels of adjusted mean viability (p \> 0.30) occurred at the five concentrations ≤3 μM As^III^ examined. When combined (using either *n* = 54 or *n* = 28 plates), the overall mean level of relative viability at concentrations ≤3 μM As^III^ significantly exceeded that exhibited by unexposed (control) cells (p ≤ 10^−6^). Although the LN, Cubic, LC, and HC models were each very predictive (R^2^ \> 0.97), none were statistically consistent with the entire corresponding data set examined (p \< 10^−5^). The LC model fit to each data set contained a linear coefficient that is positive (*i.e*., hormetic, which in the present context, indicates increased viability with increasing concentration at low concentrations), but not significantly so ([Table 3](#tbl0015){ref-type="table"}). LC model fits were not significantly better than corresponding Cubic-model fits (F~12,11~ = 0.53 and p = 0.85 with *n* = 54, F~12,11~ = 0.18 and p = 0.997 with *n* = 28). The HC model, which also exhibits low-dose hormetic behavior, provided the best fit to the combined data (R^2^ = 0.995) ([Table 3](#tbl0015){ref-type="table"}), and provided a significantly better fit than the Cubic model (F~12,10~ = 5.62 and p = 0.0051 with *n* = 54, F~12,10~ = 30.14 and p = 0.00081 with *n* = 28).Fig. 1Observed viability data (open points) and corresponding LNS-model fit (dashed curve) for plate \#4, compared to data values (solid points) that are all adjusted to reflect this fitted model with assumed parameter values of *P* = *P*~o~ = 0 (solid curve).Fig. 1Fig. 2Model fits to adjusted viability data from all 54 plates (top plot), and from 28 plates for which the LNS model yielded fits (to corresponding unadjusted data sets) that are all relatively predictive (R^2^ ≥ 0.91) and have relatively steep initial slopes (*b* ≥ 2---see [Table 1](#tbl0005){ref-type="table"}) (bottom plot). Error bars denote ±1 SEM. Fitted models shown in each plot are: lognormal (dashed curve), cubic-hormetic (solid curve), and cubic (dotted curve, which nearly coincides with the dashed and solid curve at *C* ≤ 3 μM and *C* ≥ 4 μM, respectively).Fig. 2Table 2Summary of adjusted viability data ($\text{P}\text{S}_{i,j}^{\text{adj}}$)*.*[a](#tblfn0020){ref-type="table-fn"}Table 2iC~i~ (μM)All plates (*n* = 54)[b](#tblfn0025){ref-type="table-fn"}Plates with R^2^ ≥ 0.91 and *b* ≥ 2 (*n* = 28)[b](#tblfn0025){ref-type="table-fn"}Mean (%)SEM (%)N*~j~*p~adj~Mean (%)SEM (%)N*~j~*p~adj~10.25107.21.85130.935108.71.9260.91020.50108.22.29280.930108.61.47160.91031104.21.61380.376104.41.67220.06142107.41.69440.935105.81.72260.91053101.71.74450.93599.61.62260.91064103.11.65460.890100.71.41260.9107596.41.44500.93597.21.28280.9108794.51.46510.04192.71.56280.02791088.91.82530.93586.21.99280.910101555.22.66540.93563.43.67280.051112036.62.54540.93528.33.06280.91012255.211.50540.5473.501.63280.91013303.400.79540.0013.470.79280.062[^5][^6]Table 3Model fits to adjusted viability data ($\text{P}\text{S}_{i,j}^{\text{adj}}$)*.*[a](#tblfn0030){ref-type="table-fn"}Table 3ModelPlates included[b](#tblfn0035){ref-type="table-fn"}ParameterEstimateSEp~=0~R^2^p~fit~LN54GM15.770.705\<10^−9^0.979∼0GSD1.4350.061∼0LN28GM15.300.860\<10^−8^0.977∼0GSD1.4420.070∼0Cubic54*b (*×10^4^)1.5000.154\<10^−8^0.983∼028*b (*×10^4^)1.6120.208\<10^−5^0.986∼0LC54*a (*×10^3^)2.8893.930.480.983∼0*b (*×10^4^)1.6030.21810^−5^28*a (*×10^3^)1.6954.200.690.986∼0*b (*×10^4^)1.6810.280\<10^−4^HC54*a*1.2078.990.900.992\<10^−5^*d*0.167818.90.99*b (*×10^4^)1.5020.11610^−7^28*a*1.0531.690.550.9950.0008*d*0.79634.240.19*b (*×10^4^)1.6810.116\<10^−6^[^7][^8]

4. Discussion and conclusions {#sec0040}
=============================

The current study used a greater number of replicate plates than in any previously reported study of *in vitro* As^III^ cytotoxicity and assessed cytotoxicity at many different concentrations. Markedly variable and unexplained dose-response patterns were observed concerning unadjusted data on HEK001 cell viability after As^III^ exposure, The LNS model plausibly describes diverse dose-response patterns of As^III^ cytotoxicity observed for an estimated fraction 1--*P*--*P*~o~ of HEK001 cells in each test that appeared to exhibit a typical level of resistance to As^III^ cytotoxicity. Each test-specific fraction *P*~o~ of apparently highly resistant cells was estimated after adjusting each corresponding set of viability data to exclude an estimated proportion *P* of tested cells that appeared to be relatively highly susceptible to cytotoxicity induced at very low As^III^ concentrations (as low as 0.25 μM). Such unexpected and unexplained phenotypic heterogeneity in apparent ultra-low-dose sensitivity to As^III^ was characterized as inter-test variation in the fraction *P*, estimated to range from 0 to 42%, and to average approximately 17% ([Table 1](#tbl0005){ref-type="table"}). This heterogeneity challenges the hypothesis that As^III^ cytotoxic effects have a dose-response threshold (*i.e*., do not occur at relatively low doses), to the extent that the fractions of evidently highly As^III^-susceptible HEK001 cells that were estimated to occur in this study accurately model hypersensitive cell phenotypes that also occur *in vivo*. Only if such relatively highly susceptible subpopulations of cultured HEK001 cells are not relevant *in vivo*---for example, if they are an unrealistic artifact of this line of cultured cells, or of the *in vitro* cell culture conditions used---would the good fits obtained in this study by the LNS model to adjusted HEK001 cell-viability data provide evidence consistent with a threshold-like dose-response for As^III^ cytotoxicity, conditional on the assumption that *P* = 0 under biologically relevant conditions *in vivo*. In contrast, patterns of As^III^-induced cell toxicity observed in this study indicate that As^III^ is cytotoxic to a relatively small and relatively highly sensitive subset of HEK001 cells in approximate linear proportion to the As^III^ concentration (consistent with slope parameter *b* in Eq. [(1)](#eq0005){ref-type="disp-formula"}). To the extent that "typical-sensitivity" HEK001 cells posited by the LNS model do exist, data obtained in this study do not provide evidence that low concentrations of As^III^ are toxic to these cells in linear proportion to As^III^ concentration. Consequently, results obtained in this study are novel and interesting, and merit further study to address the question of whether and to what extent subpopulations of cells that are relatively highly sensitive to As^III^ (in contrast to cells that exhibit more typical levels of sensitivity to As^III^) exist in other cell lines and *in vivo*.

One possible explanation for the substantial variability in estimated values of *P* obtained in this study is that variation in values of *P*, as well as our observation of statistically significantly increased adjusted viability in the (presumptive) remainder of "typical‐sensitivity" cells exposed to ≤3 vs. 0 μM As^III^, was due to karyotypic heterogeneity present in the cell line. The cell line was derived originally from cells from the scalp of a 65-year-old male [@bib0140] that were transfected with a plasmid p1321 containing human papillomavirus (HPV) 16 E6 and E7 genes, which may have resulted in the heterogeneity of the karyotype. Alternatively, the observed heterogeneity might be a result of cell passages, or possibly to artifacts of variable aspects of *in vitro* testing such as plating-induced damage to a fraction (*P*) of plated HEK001 cells. Additional experiments will be required to determine the cause of substantial variation in the apparent value of *P* that was observed in this study.

Ideally, a detailed study of this type would be repeated using multiple cell lines and multiple viability and viability assay methods in parallel, despite the fact that low-concentration As^III^-induced cytotoxicity is well known to involve induction of apoptotic pathways [@bib0190], [@bib0195], [@bib0200], [@bib0205], [@bib0210]. Even using a single cell line and a single assay method for reasons of practical feasibility for a first study conducted at this level of detail, the study design was quite expensive and very labor intensive. Nevertheless, results from this study represent a monumental effort that clearly yielded interesting and unexpected results. Future studies can extend this approach to additional cell lines and assay methods.

Appendix A. Supplementary data {#sec0050}
==============================

The following is Supplementary data to this article:

The research was funded (without input to study design, data analysis, or conclusions) by Electric Power Research Institute (EPRI) contracts MA10003705 (Exponent) and MA10003723 (UNMC). Our sincere thanks to Dr. Mirek Styblo at the University of North Carolina for the analysis of the arsenic concentrations in Dulbecco's PBS and the cell culture medium and to Dr. Bhavana Dave and the Cytogenetics Laboratory at the University of Nebraska Medical Center for the karyotyping of the HEK001 cell line.

Supplementary data associated with this article can be found, in the online version, at [http://dx.doi.org/10.1016/j.toxrep.2016.12.003](10.1016/j.toxrep.2016.12.003){#intr0005}.

[^1]: Current address: 2310 Commonwealth Avenue, Newton, MA 02466, USA.

[^2]: LNS model variables (see Methods); those labeled without units are unitless; rational-valued entries listed are shown rounded to three significant digits. N~x~ = experiment \#; N~p~ = \# cell-culture passages for cells used in this experiment; *i~j~* = initial index of concentrations *C~i~* (1 ≤ *i~j~* ≤ 13) modeled for experiment *j* when data were subsequently combined over multiple experiments using Eq. [(2)](#eq0010){ref-type="disp-formula"} (see Methods, Results); R^2^ = squared coefficient of correlation (fraction of variance explained by regression); p~fit,adj~ = p-value of chi-square goodness of fit test adjusted for *n* = 54 independent tests (values ≤10^−10^ are listed as ∼0); AM = arithmetic mean; SD = standard deviation; SEM = standard error of the mean; − = not applicable.

[^3]: Summary statistics for the subset of 28 "best-fit" plates (Plates 1, 2, 3, 4, 6, 10, 11, 12, 13, 14, 16, 17, 19, 20, 21, 25, 28, 29, 33, 39, 44, 47, 48, 49, 50, 52, 53, and 54) for which R^2^ ≥ 0.91 and B ≥ 2 (see Methods).

[^4]: Cell viability in a total of 4965 \[=54(8×9 + 4×5) − 3\] well measures were obtained in this study, excluding three defective measures involving *C~i~* on plate *j*, specifically for: {*i*,*j*} = {1,30}, {5,16}, and {8,15}. For the "best-fit" subset of 28 plates, the corresponding total number of well measures is 2351.

[^5]: Mean = weighted arithmetic mean of adjusted percent-viability data using inverse estimated variances as weights; *C~i~* = *i*^th^ test concentration of As^III^; SEM = standard error of the mean; N*~j~* = \# plates from which data at concentration *C~i~* were averaged (only concentrations *i* = *i~j~* through *i* = 13 were included from each *j*^th^ plate---see Methods and [Table 1](#tbl0005){ref-type="table"}); p~adj~ = p-value of Shapiro-Wilk test of approximate normality of estimated weighted means, adjusted for 13 independent tests. Mean values are shown to ≥0.1% accuracy or 3 significant digits, and SEM values to ≥0.01% accuracy.

[^6]: See [Table 1](#tbl0005){ref-type="table"}.

[^7]: Models LN, Cubic, LC, and HC are defined by Equations 4--7, respectively (Methods). those labeled without units are unitless. SE = standard error; p~0~ = p-value from a *t*-test of the null hypotheses that the parameter value is zero (values ≤10^−10^ are listed as ∼0); R^2^ = squared coefficient of correlation (fraction of variance explained by regression); p~fit~ = p-value of chi-square goodness of fit test. Parameter and SE estimates are rounded to 4 and at least 3 significant digits, respectively.

[^8]: See [Table 2](#tbl0010){ref-type="table"}.
